Discontinuation of infliximab therapy after acquisition of low disease activity by infliximab in rheumatoid arthritis study: RRR (remission induction by remicade) study

Discontinuation of infliximab therapy after acquisition of low disease activity by infliximab in rheumatoid arthritis study: RRR (remission induction by remicade) study - Remission Induction by Remicade in RA Study (RRR study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002110

Enrollment

100

Registered

2009-06-23

Start date

2006-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria will be enrolled in this study: 1) Patients with RA diagnosed according to the criteria of the American College of Rheumatology (ACR) (1987) 2) DAS28 score remained less than 3.2 for 24 weeks and who consented to discontinuation of infliximab treatment. 3) Control with MTX for more than 12 weeks 4) more than 18 years

Exclusion criteria

Exclusion criteria: Patients who met the following criteria are excluded. 1) patients who are already in remission and do not use infliximab 2) control with less than 5mg/day of PSL 3) PSL was increased within 4 weeks before the study 4) patients who are not appropriate to the study by a doctor's judgement

Design outcomes

Primary

Measure	Time frame
After discontinuing infliximab, 1. DAS28 (ESR) remains <3.2 for 1 year, 2. Yearly progression of van der Heijde-modified total Sharp score (TSS) remains <0.5 for 1 year.	—

Secondary

Measure	Time frame
After discontinuing infliximab, 1. DAS28 (ESR) remains <3.2 for 2 year, 2. Yearly progression of van der Heijde-modified total Sharp score (TSS) remains <0.5 for 2 year.	—

Countries

Japan

Contacts

Public ContactKazuyoshi Saito

School of Medicine, University of Occupational and Environmental Health, Japan First Department of Internal Medicine

tanaka@med.uoeh-u.ac.jp093-603-1611

Outcome results